Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1)–
programmed cell death ligand-1 (PD-L1) axis have shown promising results in non-small …
programmed cell death ligand-1 (PD-L1) axis have shown promising results in non-small …
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
M Provencio, E Nadal, A Insa… - The Lancet …, 2020 - thelancet.com
Background Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally
advanced stage disease. We aimed to assess the antitumour activity and safety of …
advanced stage disease. We aimed to assess the antitumour activity and safety of …
Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell …
S Gadgeel, D Rodríguez-Abreu, G Speranza… - Journal of clinical …, 2020 - ascopubs.org
PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum
significantly improved overall survival (OS) and progression-free survival (PFS) compared …
significantly improved overall survival (OS) and progression-free survival (PFS) compared …
Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non–small-cell lung cancer (NADIM phase II trial)
M Provencio, R Serna-Blasco, E Nadal… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in
resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials. gov …
resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials. gov …
[HTML][HTML] Pembrolizumab plus pemetrexed and platinum in nonsquamous non–small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study
MC Garassino, S Gadgeel, G Speranza… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically on the based on the primary end point, may be published when key planned …
report, typically on the based on the primary end point, may be published when key planned …
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre …
SP Aix, TE Ciuleanu, A Navarro, S Cousin… - The Lancet …, 2023 - thelancet.com
Background Lurbinectedin is a synthetic marine-derived anticancer agent that acts as a
selective inhibitor of oncogenic transcription. Lurbinectedin monotherapy (3· 2 mg/m 2 every …
selective inhibitor of oncogenic transcription. Lurbinectedin monotherapy (3· 2 mg/m 2 every …
Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer
Purpose: Met receptor phosphorylation is associated with poor prognosis in human small
cell lung cancer (SCLC). The aim of our work was to investigate the effects of hepatocyte …
cell lung cancer (SCLC). The aim of our work was to investigate the effects of hepatocyte …
[HTML][HTML] A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed …
Background While osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small …
tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small …
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
R Laza‐Briviesca, A Cruz‐Bermúdez… - Clinical and …, 2021 - Wiley Online Library
Background Immunotherapy is being tested in early‐stage non‐small cell lung cancer
(NSCLC), and achieving higher rates of complete pathological responses (CPR) as …
(NSCLC), and achieving higher rates of complete pathological responses (CPR) as …
Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy
M Casarrubios, A Cruz-Bermúdez, E Nadal, A Insa… - Clinical Cancer …, 2021 - AACR
Purpose: Characterization of the T-cell receptor (TCR) repertoire may be a promising source
for predictive biomarkers of pathologic response to immunotherapy in locally advanced non …
for predictive biomarkers of pathologic response to immunotherapy in locally advanced non …